Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach

Rahul Koushik; Arthur J. Matas

doi:10.1016/j.trre.2005.05.002

Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach

Rahul Koushik, Arthur J. Matas

Surgery

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Focal segmental glomerular sclerosis (FSGS) causes kidney failure in 2.5% of all end-stage kidney disease patients. FSGS recurs in 20% to 30% of kidney allografts. In a third of kidney recipients with recurrent FSGS, graft loss is attributed to recurrent disease. Complicating the understanding of recurrent FSGS are the facts that (a) many patients with end-stage kidney disease do not undergo a kidney biopsy before transplant and (b) "de novo" FSGS is not uncommon after transplant, occurring in up to 30% of allografts. This review aims to clarify the definitions of recurrent FSGS and to identify risk factors for treatable recurrent FSGS. The pathophysiology of FSGS and therapeutic strategies from clinical trials are discussed.

Original language	English (US)
Pages (from-to)	78-87
Number of pages	10
Journal	Transplantation Reviews
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.trre.2005.05.002
State	Published - Apr 2005

Bibliographical note

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.trre.2005.05.002

OpenUrl availability

Full text

Cite this

@article{05cd2af7033e4c8aaf13f34807fa5cff,

title = "Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach",

abstract = "Focal segmental glomerular sclerosis (FSGS) causes kidney failure in 2.5% of all end-stage kidney disease patients. FSGS recurs in 20% to 30% of kidney allografts. In a third of kidney recipients with recurrent FSGS, graft loss is attributed to recurrent disease. Complicating the understanding of recurrent FSGS are the facts that (a) many patients with end-stage kidney disease do not undergo a kidney biopsy before transplant and (b) {"}de novo{"} FSGS is not uncommon after transplant, occurring in up to 30% of allografts. This review aims to clarify the definitions of recurrent FSGS and to identify risk factors for treatable recurrent FSGS. The pathophysiology of FSGS and therapeutic strategies from clinical trials are discussed.",

author = "Rahul Koushik and Matas, {Arthur J.}",

year = "2005",

month = apr,

doi = "10.1016/j.trre.2005.05.002",

language = "English (US)",

volume = "19",

pages = "78--87",

journal = "Transplantation Reviews",

issn = "0955-470X",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Focal segmental glomerular sclerosis in kidney allograft recipients

T2 - An evidence-based approach

AU - Koushik, Rahul

AU - Matas, Arthur J.

PY - 2005/4

Y1 - 2005/4

N2 - Focal segmental glomerular sclerosis (FSGS) causes kidney failure in 2.5% of all end-stage kidney disease patients. FSGS recurs in 20% to 30% of kidney allografts. In a third of kidney recipients with recurrent FSGS, graft loss is attributed to recurrent disease. Complicating the understanding of recurrent FSGS are the facts that (a) many patients with end-stage kidney disease do not undergo a kidney biopsy before transplant and (b) "de novo" FSGS is not uncommon after transplant, occurring in up to 30% of allografts. This review aims to clarify the definitions of recurrent FSGS and to identify risk factors for treatable recurrent FSGS. The pathophysiology of FSGS and therapeutic strategies from clinical trials are discussed.

AB - Focal segmental glomerular sclerosis (FSGS) causes kidney failure in 2.5% of all end-stage kidney disease patients. FSGS recurs in 20% to 30% of kidney allografts. In a third of kidney recipients with recurrent FSGS, graft loss is attributed to recurrent disease. Complicating the understanding of recurrent FSGS are the facts that (a) many patients with end-stage kidney disease do not undergo a kidney biopsy before transplant and (b) "de novo" FSGS is not uncommon after transplant, occurring in up to 30% of allografts. This review aims to clarify the definitions of recurrent FSGS and to identify risk factors for treatable recurrent FSGS. The pathophysiology of FSGS and therapeutic strategies from clinical trials are discussed.

UR - http://www.scopus.com/inward/record.url?scp=23944514992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944514992&partnerID=8YFLogxK

U2 - 10.1016/j.trre.2005.05.002

DO - 10.1016/j.trre.2005.05.002

M3 - Review article

AN - SCOPUS:23944514992

SN - 0955-470X

VL - 19

SP - 78

EP - 87

JO - Transplantation Reviews

JF - Transplantation Reviews

IS - 2

ER -

Focal segmental glomerular sclerosis in kidney allograft recipients: An evidence-based approach

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this